Galderma will acquire ZO Skin Health for $1.5 billion in an all-cash deal, the dermatology company behind Cetaphil, Restylane and Dysport announced. The agreement puts one of the largest physician-dispensed skin-care brands under the same roof as injectables and mass-market cleansers.

Nothing changes for consumers yet. ZO products remain available through physicians' offices and at zoskinhealth.com. The deal is expected to close in the fourth quarter of 2026 or early 2027, pending regulatory approvals.

Who is selling, and for how much?

Blackstone and the Obagi family are selling their stakes. Blackstone says ZO's revenue more than doubled during its ownership. The Irvine, California-based brand recorded roughly $330 million in net sales over the 12 months ending in June 2026.

Dermatologist Zein Obagi, MD, founded the company more than two decades ago. The lineup spans 40-plus products, all made in the U.S., built heavily on retinol and acid protocols.

What does ZO bring to Galderma?

Distribution scale is the headline number: ZO sells through more than 16,500 physician, medical spa and online accounts in over 40 countries. That footprint gives Galderma a bigger position in medical-grade skin care — the category where doctors recommend and sell products directly in the office.

Galderma already owns Alastin, known for peptide-based formulas that support skin around in-office procedures. ZO fills a different slot with full daily regimens rather than procedure support.

What did the principals say?

Galderma CEO Flemming Ørnskov, MD, MPH, framed the deal as portfolio strategy. "This acquisition is another important step towards building the world's most innovative dermatology portfolio," he said.

Dr. Obagi will stay on as ZO's founder and medical director. "Galderma is an organization I have long admired for its complete dedication to dermatology," he said. "I am confident we have found a home where our philosophy will endure and grow."

What happens after closing?

Galderma plans to increase investment in the brand during its first year of ownership and targets reignited growth in year two. Until closing, ZO Skin Health operates as usual.

For the physician-dispensed channel, the deal signals how aggressively large dermatology groups are consolidating medical-grade skin care — the same playbook Galderma ran with Alastin, now at ten times the scale.

By Amara Osei